Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

Arora, Brijesh; Kumar, Lalit; Sharma, Aruna; Wadhwa, Jyoti; Kochupillai, V.

doi:10.1093/annonc/mdh068

Cited by 95 publications

(90 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mild to moderate severity of superficial edema, most commonly on the eyelids, is reported in 48-65% of patients treated with imatinib. 11,12 As reported in the present case, it is generally self-limited, not implying withdrawal of the drug. Other common side effects, mainly dose-dependent, include nausea, vomiting, nonspecific skin rash, and pigmentary changes.…”

Section: Discussionsupporting

confidence: 70%

Imatinib: a novel treatment approach for generalized morphea

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 70%

Imatinib: a novel treatment approach for generalized morphea

et al. 2014

View full text Add to dashboard Cite

show abstract

“…5 In a study of 118 CML patients on imatinib therapy, superficial edema and rash were observed in 48 and 12.7% of patients, respectively. 79 There was also a high prevalence of pigmentary changes, which included 40.9% depigmentation (localized or generalized) and 3.6% hyperpigmentation. Pigmentary changes, skin rash and related events are most likely due to imatinib inhibition of c-KIT in the skin.…”

Section: C-kit Inhibition: Dermatologic Toxicity Myelosuppression Anmentioning

confidence: 99%

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

2009

View full text Add to dashboard Cite

Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the efficacy and safety profile of each agent when choosing the best therapeutic option for individual patients. Each agent targets tyrosine kinases within the cell uniquely to cause the desired antiproliferative effect. In addition to inhibiting the BCR-ABL kinase, imatinib and nilotinib target the same array of other tyrosine kinases, including c-KIT and plateletderived growth factor receptor (PDGFR), albeit with differing potencies. While targeting BCR-ABL with the highest potency among approved agents in CML, dasatinib also targets a broad array of off-target kinases, including SRC family members, PDGFR and EPHB4. The differences in kinase inhibition profiles among these agents in vitro probably account for the differing clinical safety profiles of these agents. This paper reviews the various kinases inhibited by imatinib, nilotinib and dasatinib, and describes the potential impact of kinase inhibition on the efficacy and safety of each agent.

show abstract

“…In five recently published articles, patients on imatinib were noted to develop cutaneous pigmentation [4,5], diffuse hyperpigmentation on the hard palate mucosa [5][6][7] or melanonychia [8].…”

Section: Introductionmentioning

confidence: 99%